Jaguar health shares replay link for september 7, 2023 presentation at emerging growth conference

Click here to access webcast replay top line results expected late october 2023 for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / september 11, 2023 / jaguar health, inc. (nasdaq:jagx), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (gi) prescription medicines, today announced that the recording of the company's september 7, 2023 virtual presentation at the emerging growth conference can be accessed by clicking here . about the jaguar health family of companies jaguar health, inc. (jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
JAGX Ratings Summary
JAGX Quant Ranking